+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North American Urothelial Carcinoma Market 2020-2026

  • ID: 5148143
  • Report
  • August 2020
  • Region: North America, United States
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • MORE
North American Urothelial Carcinoma Market Size, Share & Trends Analysis Report by Diagnosis (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others) and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other) and Forecast, 2020-2026.

North American urothelial carcinoma market is estimated to grow significantly at a CAGR of around 9.4% during the forecast period. Major factors that are augmenting the growth of the North American urothelial carcinoma market include increasing healthcare expenditure, raising awareness of cancer among the population, and surging aging population base coupled with the significant prevalence of urothelial carcinoma across the region. Moreover, the changing lifestyle, such as the consumption of alcohol and tobacco, is a major factor that increases the possibilities of diseases such as cancer. Thereby, resulting in driving the market for urothelial carcinoma across the region.

North American urothelial carcinoma market is segmented on the basis of countries in the region, namely the US and Canada. The US urothelial carcinoma market contributed the major share in the North America urothelial carcinoma market in 2019. American Cancer Society has provided bladder cancer statistics for 2019 in the US. The society estimates that around 17,670 mortalities will be due to bladder cancer in 2019. Moreover, around 73% of all these mortalities will be in men and the rest will be in women. It has been observed that the rates of new bladder cancers and mortalities caused by them are dropping slightly in women in recent years. Still, North America contributes a significant share in the global urothelial carcinoma market.

North American urothelial carcinoma market is segmented into diagnosis and treatment. Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. Transitional cell urothelial carcinoma is the most common type of urothelial carcinoma. As per the Canadian Cancer Society, it makes up over 90% of all urothelial carcinomas.

The companies which are contributing to the growth of the North American urothelial carcinoma market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc., and Spectrum Pharmaceuticals, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of the North American urothelial carcinoma market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation:

1. North American Urothelial Carcinoma Market Research and Analysis by Diagnosis
2. North American Urothelial Carcinoma Market Research and Analysis by Treatment

The Report Covers:
  • Comprehensive research methodology of the North American urothelial carcinoma market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the North American urothelial carcinoma market.
  • Insights about market determinants which are stimulating the North American urothelial carcinoma market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. North American Urothelial Carcinoma Market by Diagnosis
5.1.1. Cystoscopy
5.1.2. Biopsy
5.1.3. Urinalysis
5.1.4. Urine Cytology
5.1.5. Intravenous Pyelogram (IVP)
5.1.6. Others (Biomarkers)
5.2. North American Urothelial Carcinoma Market by Treatment
5.2.1. Surgery
5.2.2. Chemotherapy
5.2.3. Immunotherapy
5.2.4. Radiation Therapy
5.2.5. Others (Targeted Therapy)

6. Regional Analysis
6.1. United States
6.2. Canada

7. Company Profiles
7.1. Astellas Pharma Inc.
7.2. AstraZeneca PLC
7.3. Bayer AG
7.4. Bristol-Myers Squibb Co.
7.5. Eli Lilly and Co.
7.6. EMD Serono, Inc.
7.7. F. Hoffmann-La Roche Ltd.
7.8. Genentech Inc.
7.9. GlaxoSmithKline Plc
7.10. Johnson & Johnson Services, Inc.
7.11. Merck & Co., Inc.
7.12. Pfizer Inc.
7.13. Spectrum Pharmaceuticals, Inc.
7.14. Taris Biomedical LLC
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • EMD Serono, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Taris Biomedical LLC
Note: Product cover images may vary from those shown
Adroll
adroll